BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee JS, Park SS, Lee YK, Norton JA, Jeffrey SS. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA. Mol Oncol 2019;13:1623-50. [PMID: 31243883 DOI: 10.1002/1878-0261.12537] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Park R, Al-Jumayli M, Miller K, Saeed A, Saeed A. Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma. Cancer Treat Res Commun 2021;27:100342. [PMID: 33611092 DOI: 10.1016/j.ctarc.2021.100342] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol 2021;18:297-312. [PMID: 33473219 DOI: 10.1038/s41571-020-00457-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 38.0] [Reference Citation Analysis]
3 Kaufman DG. The need for rapid therapeutic efficacy testing for cancer therapy. Exp Mol Pathol 2020;113:104382. [PMID: 31982397 DOI: 10.1016/j.yexmp.2020.104382] [Reference Citation Analysis]
4 Simons-Linares CR, Yadav D, Lopez R, Bhatt A, Jang S, El-Khider F, Sanaka M, Stevens T, Vargo J, Chahal P. The utility of intracystic glucose levels in differentiating mucinous from non-mucinous pancreatic cysts. Pancreatology 2020;20:1386-92. [PMID: 32919884 DOI: 10.1016/j.pan.2020.08.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Szkukalek J, Dóczi R, Dirner A, Boldizsár Á, Varga Á, Déri J, Lakatos D, Tihanyi D, Vodicska B, Schwáb R, Pajkos G, Várkondi E, Vályi-Nagy I, Valtinyi D, Nagy Z, Peták I. Personalized First-Line Treatment of Metastatic Pancreatic Neuroendocrine Carcinoma Facilitated by Liquid Biopsy and Computational Decision Support. Diagnostics (Basel) 2021;11:1850. [PMID: 34679548 DOI: 10.3390/diagnostics11101850] [Reference Citation Analysis]
6 Lee JS, Kim M, Seong MW, Kim HS, Lee YK, Kang HJ. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction. Clin Chem Lab Med 2020;58:527-32. [PMID: 31874093 DOI: 10.1515/cclm-2019-0896] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
7 Osei-bordom DC, Sachdeva G, Christou N. Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma. Front Med 2022;8:788869. [DOI: 10.3389/fmed.2021.788869] [Reference Citation Analysis]
8 Okusaka T, Furuse J. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 2020;55:369-382. [PMID: 31997007 DOI: 10.1007/s00535-020-01666-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
9 Manoochehri M, Wu Y, Giese NA, Strobel O, Kutschmann S, Haller F, Hoheisel JD, Moskalev EA, Hackert T, Bauer AS. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis. Mol Oncol 2020;14:1252-67. [PMID: 32243066 DOI: 10.1002/1878-0261.12684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Wang S, Zheng Y, Yang F, Zhu L, Zhu XQ, Wang ZF, Wu XL, Zhou CH, Yan JY, Hu BY, Kong B, Fu DL, Bruns C, Zhao Y, Qin LX, Dong QZ. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther 2021;6:249. [PMID: 34219130 DOI: 10.1038/s41392-021-00659-4] [Reference Citation Analysis]
11 Zhang Y, Su H, Wang H, Xu C, Zhou S, Zhao J, Shen S, Xu G, Wang L, Zou X, Zhang S, Lv Y. Endoscopic Ultrasound-Guided Acquisition of Portal Venous Circulating Tumor Cells as a Potential Diagnostic and Prognostic Tool for Pancreatic Cancer. Cancer Manag Res 2021;13:7649-61. [PMID: 34675662 DOI: 10.2147/CMAR.S330473] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kirchweger P, Kupferthaler A, Burghofer J, Webersinke G, Jukic E, Schwendinger S, Weitzendorfer M, Petzer A, Függer R, Rumpold H, Wundsam H. Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage. Eur J Surg Oncol 2021:S0748-7983(21)00947-1. [PMID: 34876329 DOI: 10.1016/j.ejso.2021.11.138] [Reference Citation Analysis]
13 Wu Y, Hung Y, Chiu N, Lee R, Li C, Chao Y, Shyr Y, Wang S, Chen S, Lin S, Chen Y, Kang Y, Hsu S, Yen S, Wu J, Lee K, Tseng H, Tsai J, Tang J, Chiou J, Burnouf T, Chen Y, Wang P, Lu L. Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma. European Journal of Cancer 2022;166:208-18. [DOI: 10.1016/j.ejca.2022.01.030] [Reference Citation Analysis]
14 Singh PK, Patel A, Kaffenes A, Hord C, Kesterson D, Prakash S. Microfluidic Approaches and Methods Enabling Extracellular Vesicle Isolation for Cancer Diagnostics. Micromachines 2022;13:139. [DOI: 10.3390/mi13010139] [Reference Citation Analysis]
15 Lee JS, Rhee TM, Pietrasz D, Bachet JB, Laurent-Puig P, Kong SY, Takai E, Yachida S, Shibata T, Lee JW, Park HC, Zang DY, Jeon K, Lee J, Kim M, Kim HS, Kang HJ, Lee YK. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Sci Rep 2019;9:16971. [PMID: 31740696 DOI: 10.1038/s41598-019-53271-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
16 Wei T, Zhang J, Li J, Chen Q, Zhi X, Tao W, Ma J, Yang J, Lou Y, Ma T, Li X, Zhang Q, Chen W, Que R, Gao S, Bai X, Liang T. Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. Mol Oncol 2020;14:1966-77. [PMID: 32593194 DOI: 10.1002/1878-0261.12757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zhao Y, Yang M, Wang S, Abbas SJ, Zhang J, Li Y, Shao R, Liu Y. An Overview of Epigenetic Methylation in Pancreatic Cancer Progression. Front Oncol 2022;12:854773. [DOI: 10.3389/fonc.2022.854773] [Reference Citation Analysis]
18 Taghizadeh H, Müllauer L, Mader RM, Schindl M, Prager GW. Applied precision medicine in metastatic pancreatic ductal adenocarcinoma. Ther Adv Med Oncol 2020;12:1758835920938611. [PMID: 32699558 DOI: 10.1177/1758835920938611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Hata T, Mizuma M, Iseki M, Takadate T, Ishida M, Nakagawa K, Hayashi H, Morikawa T, Motoi F, Unno M. Circulating tumor DNA as a predictive marker for occult metastases in pancreatic cancer patients with radiographically non-metastatic disease. J Hepatobiliary Pancreat Sci 2021;28:648-58. [PMID: 34022116 DOI: 10.1002/jhbp.993] [Reference Citation Analysis]
20 Wijewardene AA, Chehade M, Gild ML, Clifton-Bligh RJ, Bullock M. Translational Utility of Liquid Biopsies in Thyroid Cancer Management. Cancers (Basel) 2021;13:3443. [PMID: 34298656 DOI: 10.3390/cancers13143443] [Reference Citation Analysis]
21 Heredia-Soto V, Rodríguez-Salas N, Feliu J. Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice? Cancers (Basel) 2021;13:1986. [PMID: 33924143 DOI: 10.3390/cancers13081986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Sahni S, Pandya AR, Hadden WJ, Nahm CB, Maloney S, Cook V, Toft JA, Wilkinson-White L, Gill AJ, Samra JS, Dona A, Mittal A. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma. Int J Cancer 2021;148:1508-18. [PMID: 33128797 DOI: 10.1002/ijc.33368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Zhu L, Kan KJ, Grün JL, Hissa B, Yang C, Győrffy B, Loges S, Reißfelder C, Schölch S. GAS2L1 Is a Potential Biomarker of Circulating Tumor Cells in Pancreatic Cancer. Cancers (Basel) 2020;12:E3774. [PMID: 33333841 DOI: 10.3390/cancers12123774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Pelle M, Das AAK, Madden LA, Paunov VN. Bioimprint Mediated Label-Free Isolation of Pancreatic Tumor Cells from a Healthy Peripheral Blood Cell Population. Adv Biosyst 2020;4:e2000054. [PMID: 33016004 DOI: 10.1002/adbi.202000054] [Reference Citation Analysis]
25 Woo SM, Kim MK, Park B, Cho EH, Lee TR, Ki CS, Yoon KA, Kim YH, Choi W, Kim DY, Hwang JH, Cho JH, Han SS, Lee WJ, Park SJ, Kong SY. Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohort Study. Cancers (Basel) 2021;13:5466. [PMID: 34771630 DOI: 10.3390/cancers13215466] [Reference Citation Analysis]
26 He K, Zhang S, Shao LL, Yin JC, Wu X, Shao YW, Yuan S, Yu J. Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. Cancer Lett 2020;472:108-18. [PMID: 31837443 DOI: 10.1016/j.canlet.2019.12.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Al-Shaheri FN, Alhamdani MSS, Bauer AS, Giese N, Büchler MW, Hackert T, Hoheisel JD. Blood biomarkers for differential diagnosis and early detection of pancreatic cancer. Cancer Treat Rev 2021;96:102193. [PMID: 33865174 DOI: 10.1016/j.ctrv.2021.102193] [Reference Citation Analysis]
28 Yee NS. Liquid Biopsy: A Biomarker-Driven Tool towards Precision Oncology. J Clin Med 2020;9:E2556. [PMID: 32784545 DOI: 10.3390/jcm9082556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Earl J, Barreto E, Castillo ME, Fuentes R, Rodríguez-Garrote M, Ferreiro R, Reguera P, Muñoz G, Garcia-Seisdedos D, López JV, Sainz B Jr, Malats N, Carrato A. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival. Cancers (Basel) 2021;13:1612. [PMID: 33807330 DOI: 10.3390/cancers13071612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Fang Z, Meng Q, Zhang B, Shi S, Liu J, Liang C, Hua J, Yu X, Xu J, Wang W. Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis. Aging (Albany NY) 2020;13:2031-48. [PMID: 33318293 DOI: 10.18632/aging.202199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Hue JJ, Sugumar K, Kyasaram RK, Shanahan J, Lyons J, Ocuin LM, Rothermel LD, Hardacre JM, Ammori JB, Rao G, Winter JM, Markt SC. Weight Loss as an Untapped Early Detection Marker in Pancreatic and Periampullary Cancer. Ann Surg Oncol 2021. [PMID: 33835301 DOI: 10.1245/s10434-021-09861-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Hagey DW, Kordes M, Görgens A, Mowoe MO, Nordin JZ, Moro CF, Löhr JM, El Andaloussi S. Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer. J Extracell Vesicles 2021;10:e12142. [PMID: 34595842 DOI: 10.1002/jev2.12142] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Lin S, Gu S, Qian S, Liu Y, Sheng J, Li Q, Yang J, Ying X, Li Z, Tang M, Wang J, Chen K, Jin M. Genome-Wide Methylation Profiling of lncRNAs Reveals a Novel Progression-Related and Prognostic Marker for Colorectal Cancer. Front Oncol 2022;11:782077. [DOI: 10.3389/fonc.2021.782077] [Reference Citation Analysis]